These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16018174)

  • 1. [The characteristics of combined genetic screening of the first trimester of pregnancy after use of assisted reproductive technology programs].
    Butenko VL; Bariliak IP; Stefanovich AV
    Tsitol Genet; 2005; 39(1):21-5. PubMed ID: 16018174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multivariate analysis identifies the estradiol level at ovulation triggering as an independent predictor of the first trimester pregnancy-associated plasma protein-A level in IVF/ICSI pregnancies.
    Giorgetti C; Vanden Meerschaut F; De Roo C; Saunier O; Quarello E; Hairion D; Penaranda G; Chabert-Orsini V; De Sutter P
    Hum Reprod; 2013 Oct; 28(10):2636-42. PubMed ID: 23887070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
    Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
    Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of Rhesus status on first-trimester pregnancy screening markers free beta human chorionic gonadotropin, pregnancy-associated plasma protein-A and nuchal translucency.
    Cowans NJ; Stamatopoulou A; Spencer K
    Prenat Diagn; 2009 May; 29(5):505-7. PubMed ID: 19222026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-trimester screening markers are altered in pregnancies conceived after IVF/ICSI.
    Gjerris AC; Loft A; Pinborg A; Christiansen M; Tabor A
    Ultrasound Obstet Gynecol; 2009 Jan; 33(1):8-17. PubMed ID: 19115229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical first-trimester routine screening for Down syndrome in singleton pregnancies in northern Finland.
    Valinen Y; Rapakko K; Kokkonen H; Laitinen P; Tekay A; Ahola T; Ryynanen M
    Am J Obstet Gynecol; 2007 Mar; 196(3):278.e1-5. PubMed ID: 17346554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First trimester predictors of adverse pregnancy outcomes.
    Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
    Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First trimester screening with free beta-hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction.
    Orlandi F; Rossi C; Allegra A; Krantz D; Hallahan T; Orlandi E; Macri J
    Prenat Diagn; 2002 Aug; 22(8):718-21. PubMed ID: 12210583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of serum markers in first-trimester down syndrome screening.
    Canick JA; Lambert-Messerlian GM; Palomaki GE; Neveux LM; Malone FD; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Saade GR; Berkowitz RL; Dar P; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
    Obstet Gynecol; 2006 Nov; 108(5):1192-9. PubMed ID: 17077242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do we need readjustment of the biochemical parameters in first trimester combined aneuploidy screening test in women with polycystic ovary syndrome?
    Karsli MF; Gultekin IB; Cakmak B; Yeral MI; Seckin KD; Alt Nboga O; Kucukozkan T
    Prenat Diagn; 2014 Nov; 34(11):1073-6. PubMed ID: 24916516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
    Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
    Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-trimester screening: an overview.
    Eiben B; Glaubitz R
    J Histochem Cytochem; 2005 Mar; 53(3):281-3. PubMed ID: 15750002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).
    Dugoff L; Hobbins JC; Malone FD; Porter TF; Luthy D; Comstock CH; Hankins G; Berkowitz RL; Merkatz I; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Vidaver J; D'Alton ME
    Am J Obstet Gynecol; 2004 Oct; 191(4):1446-51. PubMed ID: 15507981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.
    Krantz D; Goetzl L; Simpson JL; Thom E; Zachary J; Hallahan TW; Silver R; Pergament E; Platt LD; Filkins K; Johnson A; Mahoney M; Hogge WA; Wilson RD; Mohide P; Hershey D; Wapner R;
    Am J Obstet Gynecol; 2004 Oct; 191(4):1452-8. PubMed ID: 15507982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
    Soergel P; Pruggmayer M; Schwerdtfeger R; Muhlhaus K; Scharf A
    Fetal Diagn Ther; 2006; 21(3):264-8. PubMed ID: 16601335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-trimester or second-trimester screening, or both, for Down's syndrome.
    Malone FD; Canick JA; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Dukes K; Bianchi DW; Rudnicka AR; Hackshaw AK; Lambert-Messerlian G; Wald NJ; D'Alton ME;
    N Engl J Med; 2005 Nov; 353(19):2001-11. PubMed ID: 16282175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.